FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to pharmaceutical industry, namely to variants of the pharmaceutical combination composition of antibacterial and necrolytic action for external and topical application. In a first or second embodiment, the composition comprises (in wt %) a base, 0.01–5.0 % lysoamideases, 0.5–6.5 % anesthetic of and 0.1–5.0 % dioxidine or a mixture thereof with 0.01–2.0 % Trilon B; in a third embodiment, the composition comprises (in wt %) a hydrophilic base, 0.01–5.0 % lysoamideases, 0.5–6.5 % anesthetic, 0.01–2.0 % miramistine or decamethoxin and 0.005–4.0 % Trilon B or EDTA; in a fourth embodiment, the composition comprises (in wt %) a hydrophilic base, 0.01–5.0 % lysoamideases, 0.5–6.5 % anesthetic, 0.01–2.5 % ofloxacin or ciprofloxacin, 0.01–2.0 % dioxin or trimethoprim, 0.5–10.5 % xymedon; in a fifth embodiment, the composition comprises (in wt %) a base, 0.01–5.0 % lysoamideases, 0.5–6.5 % anesthetic, 0.2–5.0 % netilmicin or amikacin, 0.1–2.0 % sodium lauryl sulfate, dioxidine, trimethoprim or a mixture thereof.
EFFECT: group of inventions provides an increase in antibacterial and/or antifungal activity.
15 cl, 42 ex, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMBINED COMPOSITION FOR LOCAL AND EXTERNAL USE ON BASIS OF DIOXIDINE | 2016 |
|
RU2667974C2 |
PHARMACEUTICAL COMBINED COMPOSITION FOR THE TREATMENT OF PURULENT WOUNDS ON THE BASIS OF FLUOROQUINOLONS (OPTIONS) | 2016 |
|
RU2682171C2 |
ANTIBACTERIAL AND NECROLYTIC EXTERNAL AND LOCAL LISOAMIDASE PHARMACEUTICAL COMPOSITION | 2007 |
|
RU2367457C2 |
LOCAL AND EXTERNAL PHARMACEUTICAL PRODUCT BASED OF LOW MOLECULAR INTERFERON INDUCER | 2007 |
|
RU2353354C1 |
STABLE COMBINED PHARMACEUTICAL COMPOSITION OF DIOXIDINE AND ANESTHETICS | 2017 |
|
RU2733714C2 |
PHARMACEUTICAL PREPARATION FOR LOCAL AND EXTERNAL USE, BASED ON LOW-MOLECULAR INTERFERON INDUCER | 2007 |
|
RU2348400C1 |
ANTIBACTERIAL AND NECROLYTIC LOCAL LISOAMIDASE PHARMACEUTICAL COMPOSITION | 2007 |
|
RU2367469C2 |
CYCLOPHERONE-BASED PHARMACEUTICAL COMPOSITION OF LOCAL OR EXTERNAL APPLICATION FOR TREATMENT OF PURULENT-DESTRUCTIVE AFFECTION OF MUCOUS MEMBRANE AND SKIN, GENERAL-SYSTEM DISEASES IN CASE OF IMMUNODEFICIENCY CONDITIONS (VERSIONS) | 2008 |
|
RU2414221C2 |
ANTIBACTERIAL AND NECROLYTIC LOCAL PHARMACEUTICAL COMPOSITION | 2007 |
|
RU2367456C2 |
PHARMACEUTICAL SUBSTANCE FOR TREATING INFECTED WOUNDS OF VARIOUS ORIGINS | 2018 |
|
RU2697869C1 |
Authors
Dates
2018-05-29—Published
2016-10-11—Filed